- Home
- GANX vs WHWK Comparison
GANX vs WHWK Comparison
Compare GANX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- WHWK
- Stock Information
- Founded
- GANX 2017
- WHWK 2007
- Country
- GANX United States
- WHWK United States
- Employees
- GANX N/A
- WHWK N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- WHWK Health Care
- Exchange
- GANX Nasdaq
- WHWK Nasdaq
- Market Cap
- GANX 45.8M
- WHWK 48.3M
- IPO Year
- GANX 2021
- WHWK N/A
- Fundamental
- Price
- GANX $1.94
- WHWK $1.68
- Analyst Decision
- GANX Strong Buy
- WHWK
- Analyst Count
- GANX 5
- WHWK 0
- Target Price
- GANX $8.20
- WHWK N/A
- AVG Volume (30 Days)
- GANX 314.5K
- WHWK 172.4K
- Earning Date
- GANX 05-13-2025
- WHWK 05-19-2025
- Dividend Yield
- GANX N/A
- WHWK N/A
- EPS Growth
- GANX N/A
- WHWK N/A
- EPS
- GANX N/A
- WHWK N/A
- Revenue
- GANX N/A
- WHWK $25,983,000.00
- Revenue This Year
- GANX N/A
- WHWK $30.85
- Revenue Next Year
- GANX N/A
- WHWK N/A
- P/E Ratio
- GANX N/A
- WHWK N/A
- Revenue Growth
- GANX N/A
- WHWK 6.69
- 52 Week Low
- GANX $0.89
- WHWK $1.21
- 52 Week High
- GANX $3.19
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- GANX 54.26
- WHWK N/A
- Support Level
- GANX $1.85
- WHWK N/A
- Resistance Level
- GANX $2.27
- WHWK N/A
- Average True Range (ATR)
- GANX 0.16
- WHWK 0.00
- MACD
- GANX 0.02
- WHWK 0.00
- Stochastic Oscillator
- GANX 59.17
- WHWK 0.00
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.